{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T06:16:12Z","timestamp":1783664172951,"version":"3.55.0"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In this cross-sectional observational study, we evaluated whether serum and urinary Golgi membrane protein 1 (GOLM1\/GP73) could serve as biomarkers for CKD. Chronic kidney disease (CKD) lacks simple biomarkers reflecting both systemic burden and tubular health. GP73 is stress-responsive, but its utility across CKD and acute kidney injury (AKI) has not been systematically evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We enrolled 32 healthy individuals and 172 kidney disease patients: CKD stages 1\u20133 (\n                      <jats:italic>n<\/jats:italic>\n                      = 70), 4\u20135 (\n                      <jats:italic>n<\/jats:italic>\n                      = 42), dialysis-dependent stage 5D (\n                      <jats:italic>n<\/jats:italic>\n                      = 40), and AKI or acute-on-chronic kidney disease (\n                      <jats:italic>n<\/jats:italic>\n                      = 20). Serum G73, urinary G73, urinary creatinine, and conventional renal markers were measured. Logistic regression, AUC, decision curve analysis (DCA), and ordinal regression were used. Kidney biopsies (\n                      <jats:italic>n<\/jats:italic>\n                      = 20) were immunostained for GP73.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Serum G73 progressively increased from healthy controls to CKD stages 4-5, with a modest decrease in CKD stage 5D (median: healthy 47.2, CKD1-3 62.2, CKD4-5 96.1, CKD5D 89.9 ng\/mL;\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001), whereas urinary G73 and the urine G73-to-creatinine ratio progressively declined (both\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001). Adding serum G73 to a clinical model (age, sex, BMI, hypertension, diabetes, CKD duration) significantly improved discrimination of advanced CKD (CKD4-5\/5D vs. 1\u20133): AUC increased from 0.81 to 0.85 (DeLong\n                      <jats:italic>P<\/jats:italic>\n                      = 0.026), with net DCA benefit across 0\u201385% thresholds. Adding serum G73 to a non-renal clinical covariate model improved discrimination for advanced CKD; however, sensitivity analyses showed no meaningful incremental value beyond eGFR or serum creatinine for this eGFR-defined endpoint. Serum G73 alone showed modest ability to distinguish AKI\/AonC from CKD (AUC 0.59\u20130.75). Kidney GP73 immunostaining was weak and unchanged across stages.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Serum G73 independently associates with CKD severity and adds diagnostic value to conventional models, especially for advanced CKD. The contrasting decline in urinary G73 and lack of increased renal tissue expression are consistent with a predominantly extra-renal contribution to circulating G73, while urinary G73 reflects tubular function. Serum and urinary G73 are useful non-invasive biomarkers that could improve CKD staging.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1896678","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:38:02Z","timestamp":1783661882000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Serum and urinary golgi membrane protein 1 (GOLM1\/GP73\/G73) for chronic kidney disease staging"],"prefix":"10.3389","volume":"13","author":[{"given":"Jiaqi","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Nephrology, Center of Kidney and Urology, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Center of Kidney and Urology, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Surgical Anesthesia Center, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianishaya","family":"Yeerlan","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Center of Kidney and Urology, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuping","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City","place":["OK, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjian","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Center of Kidney and Urology, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Center of Kidney and Urology, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingcheng","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Center of Kidney and Urology, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"STROBE Initiative. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ"},{"key":"B2","doi-asserted-by":"publisher","first-page":"h5527","DOI":"10.1136\/bmj.h5527","article-title":"STARD group. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies","volume":"351","author":"Bossuyt","year":"2015","journal-title":"BMJ"},{"key":"B3","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the global burden of disease study 2017","volume":"395","author":"Bikbov","year":"2020","journal-title":"Lancet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.kint.2019.07.012","article-title":"Single number for advocacy and communication\u2014worldwide more than 850 million individuals have kidney diseases","volume":"96","author":"Jager","year":"2019","journal-title":"Kidney Int."},{"key":"B5","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney","year":"2024","journal-title":"Kidney Int"},{"key":"B6","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1053\/j.ajkd.2013.12.006","article-title":"GFR estimation: from physiology to public health","volume":"63","author":"Levey","year":"2014","journal-title":"Am J Kidney Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/0004563214521795","article-title":"Neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury: a critical evaluation of current status","volume":"51","author":"Haase-Fielitz","year":"2014","journal-title":"Ann Clin Biochem."},{"key":"B8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1053\/j.ajkd.2008.07.021","article-title":"Effect of renin-angiotensin-aldosterone system inhibition, diuretics, and angiotensin-converting enzyme inhibition on urinary kidney injury molecule-1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial","volume":"53","author":"Waanders","year":"2009","journal-title":"Am J Kidney Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMra054415","article-title":"Assessing kidney function\u2013measured and estimated glomerular filtration rate","volume":"354","author":"Stevens","year":"2006","journal-title":"N Engl J Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"17088","DOI":"10.1038\/nrdp.2017.88","article-title":"Chronic kidney disease","volume":"3","author":"Romagnani","year":"2017","journal-title":"Nat Rev Dis Primers."},{"key":"B11","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1053\/j.ajkd.2021.03.026","article-title":"The promise of tubule biomarkers in kidney disease: a review","volume":"78","author":"Ix","year":"2021","journal-title":"Am J Kidney Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/ki.2012.195","article-title":"NGAL (Lcn2) monomer is associated with tubulointerstitial damage in chronic kidney disease","volume":"82","author":"Nickolas","year":"2012","journal-title":"Kidney Int."},{"key":"B13","doi-asserted-by":"publisher","first-page":"110","DOI":"10.7150\/ntno.108320","article-title":"Metabolomics for the identification of biomarkers in kidney diseases","volume":"9","author":"Pandey","year":"2025","journal-title":"Nanotheranostics."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1053\/jhep.2002.32525","article-title":"Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease","volume":"35","author":"Kladney","year":"2002","journal-title":"Hepatology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1136\/gut.2010.214916","article-title":"Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma","volume":"59","author":"Mao","year":"2010","journal-title":"Gut."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e05695","DOI":"10.1002\/advs.202505695","article-title":"Inhibition of AMPK\u03b1 pathway by podocyte GOLM1 exacerbates diabetic nephrology in mice","volume":"12","author":"Xu","year":"2025","journal-title":"Adv Sci."},{"key":"B17","first-page":"459","article-title":"Decreased survival and hepato-renal pathology in mice with C-terminally truncated GP73 (GOLPH2)","volume":"4","author":"Wright","year":"2011","journal-title":"Int J Clin Exp Pathol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e12538","DOI":"10.1111\/cpr.12538","article-title":"Golgi protein 73 and its diagnostic value in liver diseases","volume":"52","author":"Xia","year":"2019","journal-title":"Cell Prolif."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1896678\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:38:04Z","timestamp":1783661884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1896678\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":18,"alternative-id":["10.3389\/fmed.2026.1896678"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1896678","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"article-number":"1896678"}}